Newsroom
Discover the latest news and updates from Almirall.
Quick Links
Almirall press kit
PDF 2.4MB
Year in review 2024
PDF 2.7MB
Almirall at a glance
PDF 22.1MB
Discover the latest news and updates from Almirall.
Almirall press kit
PDF 2.4MB
Year in review 2024
PDF 2.7MB
Almirall at a glance
PDF 22.1MB
575 results
Published on 30 September 2026
Almirall’s scientific programme at EADV 2026 showcases advances in critical skin diseases, including atopic dermatitis, psoriasis and actinic keratosis, through more than 20 abstracts, including a late-breaking abstracts, alongside two expert-led symposia and an interactive industry AD hub session.
New clinical data show consistent efficacy and effectiveness in atopic dermatitis treatment across body regions with lebrikizumab, including high-impact areas such as the face and neck[i],[ii], while late-breaking ADlong results highlight sustained improvements in skin signs and itch with up to five years of treatment[iii].
Final two-year data from the POSITIVE clinical study demonstrate the benefits on patient overall well-being and quality of life during tildrakizumab treatment[iv],[v], and further data show evidence in patients with high disease burden and previous biologic treatment[vi],[vii].
Almirall’s commitment to medical dermatology is reflected by its Gold Sponsorship of EADV 2026 and the launch of the ‘Face It’-campaign to raise awareness of the burden of atopic dermatitis with face and neck involvement, addressing the broader impact of skin diseases on patients.
Vienna, September 30th, 2026 – Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, today announced its scientific programme at the 35th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Vienna from 30 September to 3 October 2026. As Gold Sponsor of this year’s congress, Almirall will present more than 20 abstracts on clinical and real-world evidence spanning atopic dermatitis (AD), psoriasis (PsO) and actinic keratosis (AK), and a late-breaking abstract on the ADlong 5-year long-term extension trial of AD, presenting clinical and real-world evidence across its broad commercial portfolio to support patients and dermatologists.
Almirall is sharing new data for its biologic treatments, lebrikizumab in AD and tildrakizumab in PsO, with a focus on strengthening the evidence base in areas of high unmet patient need. These new data demonstrate positive treatment outcomes across different patient populations and body regions, including high-impact areas, alongside sustained, holistic disease control– in line with Almirall’s commitment to impactful innovation that makes a real difference to patients. Evidence for topical treatments further underscores the value of a broad product portfolio for patients and dermatologists, with data showing adherence and effectiveness of CAL/BDP PAD cream in psoriasis[viii],[ix], as well as one-year safety and efficacy data of tirbanibulin when applied to up to 100 cm2 in patients with AK on face or scalp[x].
Two expert-led, educational symposia on AD and PsO, an interactive industry hub session focused on AD and a dedicated R&D corner at the exhibition booth which features Almirall’s medical dermatology pipeline, provide opportunities for scientific exchange on the new evidence and its relevance to clinical practice.
“We are advancing the scientific understanding of skin diseases to develop innovative treatments aimed at addressing real patient needs. Our EADV programme shows the breadth and depth of our work in research and development and is testament to our focus on generating evidence across our broad dermatology portfolio addressing areas of high unmet need,” said Dr Karl Ziegelbauer, Chief Scientific Officer at Almirall. “Through our close collaborations with patients and dermatologists and a pipeline solely dedicated to medical dermatology, we deepen our understanding of the broader burden of skin disease and show where science can make a meaningful difference to patients and the medical community.”
Atopic dermatitis: consistent evidence across body regions including high-impact areas like the face and neck
Almirall’s AD programme expands the clinical and real-world evidence for lebrikizumab, a high affinity, selective interleukin-13 inhibitor, with a focus on generating robust clinical evidence across body regions, high-impact areas and treatment outcomes in different patient populations.
The Phase 3b ADhope trial[xi],[xii],[xiii], the European observational ADtrust study[xiv],[xv],[xvi], and the German real-world evidence study ADlife contribute findings on skin symptoms, itch and other patient-reported outcomes[xvii],[xviii],[xix]. Together, they build understanding of the treatment’s potential efficacy and effectiveness across clinical-trial and routine-practice settings. Analyses from the ADhope and ADtrust studies specifically examine outcomes in patients with face, neck or hand involvement, addressing skin areas where disease can have a substantial impact on daily life1,2.
Findings from the ADjoin clinical long-term extension study assess skin responses with up to three years of treatment[xx]. In addition, late-breaking results from the Phase 3b ADlong extension study show sustained skin and itch responses in patients with up to five years of lebrikizumab exposure3.
Almirall will also host two AD expert meetings exploring visible disease burden, sustained responses and practical approaches to everyday management, with a particular focus on face and neck involvement:
Interactive Industry AD Hub, Thursday 1 October, 9:15 to 10 am CEST: “Looking Into the Face of AD: Tackling Clinical Cases in Moderate-to-Severe Atopic Dermatitis with Face and Neck Involvement including lebrikizumab.” Chaired by Prof. Christian Vestergaard.
AD symposium, Friday 2 October, 1 to 2 pm CEST: “The Many Faces of AD – Spotlight on Visible Burden, Deep Response, and Simplicity in Everyday Care with Lebrikizumab.” Chaired by Dr. Christine Bangert.
Psoriasis: sustained disease control and treatment outcomes beyond skin clearance
New data on tildrakizumab increases the body of scientific evidence demonstrating robust and durable efficacy across the moderate-to-severe psoriasis journey.
New analyses from reSURFACE 1 suggest that earlier intervention may contribute to better outcomes and long-term disease control in psoriasis, reinforcing the value of targeted, sustained IL-23p19 inhibition[xxi].
Beyond skin clearance, final two-year analyses from POSITIVE report benefits in patients with psoriasis affecting high-impact areas or causing high burden symptoms. Findings include improvements in psychological well-being, quality of life, work productivity and treatment satisfaction, supporting a broader view of treatment outcome and its impact on patients’ daily lives4,5,[xxii].[xxiii].
The data presented by Almirall at this year’s EADV conference further demonstrates the treatment outcomes of tildrakizumab across diverse and challenging patient populations. PROCARE-T highlights consistent effectiveness regardless of prior biologic exposure or disease duration6, while PATH-T demonstrates positive treatment outcomes even in patients with high-impact area involvement, and previous biologic failure7.
Almirall’s psoriasis symposium will explore patient perspectives, psychological well-being and treatment considerations in specific populations that represent higher treatment challenges, including older patients and those with obesity:
Psoriasis Symposium, Thursday 1 October, 5:45 to 6:45 pm CEST: “Redefining Treatment Success in Psoriasis: Moving beyond PASI to sustained disease control,” chaired by Professor Ulrich Mrowietz.
Bringing scientific breakthroughs closer to patients and dermatologists
Beyond the scientific programme, Almirall will raise awareness of the burden of AD with face and neck involvement in patients’ daily lives through its Face It campaign and dedicated booth, and a virtual reality medical training for dermatologists. Visitors to Almirall’s congress booth (X304, X306) will also be able to explore its research and development pipeline through interactive displays. Together, these activities reflect the company’s commitment to advancing the scientific understanding of skin diseases and bringing breakthrough innovation to patients and dermatologists.
Further information on Almirall’s scientific presentations and congress activities is available at EADV 2026 Media Page | Almirall
[i] Vestergaard C et al. Lebrikizumab Real-World Effectiveness and Patient Satisfaction in Patients with Moderate-to-Severe Atopic Dermatitis (AD) and Face or Hand Involvement: 16-Week Interim Results from a European Prospective Observational Study (ADtrust). EADV Congress 2026.
[ii] Vestergaard C et al. Lebrikizumab Provides Clinically Meaningful Response in Face and Hands in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: ADhope 1 Study. EADV Congress 2026 (Encore abstract).
[iii] [ADlong Study] Late-Breaking Abstract: Lebrikizumab 5-Year Long-Term Extension Results in Moderate-to-Severe Atopic Dermatitis (ADlong). EADV Congress 2026 (Late-breaker).
[iv] [POSITIVE Study - HRQoL 2-Year] Health-Related Quality of Life, Work Productivity and Treatment Satisfaction with Tildrakizumab for Up to 2 Years in Patients with Moderate-to-Severe Psoriasis in the POSITIVE Study. EADV Congress 2026 (Almirall De novo publication).
[v] [POSITIVE Study - High-Impact] Beyond Skin Clearance: Long Term Improvement of Psychological Well-Being and Health-Related Quality of Life in High-Impact Area Psoriasis Treated with Tildrakizumab (POSITIVE Study). EADV Congress 2026 (Almirall Encore publication).
[vi] [PROCARE-T Study] High effectiveness of tildrakizumab in moderate-to-severe psoriasis regardless of prior biologic therapy or disease duration: 28-week interim data from the PROCARE-T study. EADV Congress 2026 (Almirall publication).
[vii] [PATH-T Study] High effectiveness of tildrakizumab in moderate-to-severe psoriasis involving high-impact areas after failure of prior biologics: 28-week interim data from the PATH-T study. EADV Congress 2026 (Almirall publication).
[viii] Torres T, Fernández-Armenteros JM, Castilla-Fernández G, Asensio D, Galván J. Adherence to Wynzora in adults with mild-to-moderate psoriasis: Results from the ADHER-TOP study. EADV Congress 2026.
[ix] Torres T, Fernández-Armenteros JM, Castilla-Fernández G, Asensio D, Galván J. Effectiveness and PROs of Wynzora in adults with mild-to-moderate psoriasis: Results from the ADHER-TOP study. EADV Congress 2026.
[x] Welzel J, Szepietowski JC, Ferrandiz Pulido C, Pellacani G, Mosterd K, Otero R, Perez Fierro AM, Castilla-Fernández G, Siddall H, Pau-Charles I, Dirschka T. Efficacy, tolerability and 1-year long term safety with tirbanibulin 1% ointment in patients with actinic keratosis applied over a field up to 100 cm² and up to 2 treatment courses. EADV Congress 2026 (Abstract N°: AS-554).
[xi] Irvine A et al. Lebrikizumab Treatment Led to Low Disease Activity in the Majority of Patients with Moderate-to-Severe Atopic Dermatitis: Findings from the ADhope 1 Trial. EADV Congress 2026.
[xii] Zeidler C et al. Lebrikizumab Delivers Improvements Across Patient-Reported Itch, Sleep, Overall Assessment of Disease Severity and Treatment Satisfaction in ADhope 1. EADV Congress 2026.
[xiii] Munera-Campos M et al. Lebrikizumab Shows Efficacy in Patients with Moderate-to-Severe Atopic Dermatitis, Including Patients with Predominantly Moderate Disease (ADhope 1). EADV Congress 2026 (Encore abstract).
[xiv] Augustin M et al. Baseline Demographics, Clinical Characteristics and Disease Burden Among Patients with Atopic Dermatitis (AD) Treated with Lebrikizumab in Real-World Clinical Practice: Interim Results from a European Prospective Observational Study (ADtrust). EADV Congress 2026.
[xv] Gutermuth J et al. Lebrikizumab Impact on Alleviating Disease Severity, Itch Burden and Quality of Life, in Patients with Moderate-to-Severe Atopic Dermatitis (AD): 16-Week Interim Results from a European Prospective Observational Study (ADtrust). EADV Congress 2026.
[xvi] Augustin M et al. Lebrikizumab Impact on Patient-Reported Outcomes (PROs) Among Patients with Atopic Dermatitis (AD) in Real-World Clinical Practice: 16-Week Interim Results from a European Prospective Observational Study (ADtrust). EADV Congress 2026.
[xvii] Lauffer F et al. Lebrikizumab Provided High Levels of Effectiveness in Patients with Moderate-to-Severe Atopic Dermatitis: Results from ADlife, A Real-World Study. EADV Congress 2026.
[xviii] Lauffer F et al. Lebrikizumab Treatment Leads to Relevant Improvements in Patient-Reported Outcomes for Moderate-to-Severe Atopic Dermatitis in a Real-Life Setting: Findings from ADlife. EADV Congress 2026.
[xix] Lauffer F et al. Lebrikizumab Provided Meaningful Improvements in Patient-Reported Disease Control and Reduced the Number of Flares in Patients with Moderate-to-Severe Atopic Dermatitis: ADlife Real-World Study. EADV Congress 2026.
[xx] Thaçi D et al. Lebrikizumab Achieved High Levels of Absolute EASI Optimal Response in Patients with Moderate-to-Severe Atopic Dermatitis for Up to 3 Years (ADvocate 1 & 2 to ADjoin). EADV Congress 2026.
[xxi] [reSURFACE 1 Post Hoc] Association Between Psoriasis Duration and Maintenance of Control (PASI ≤2) after Tildrakizumab Withdrawal: Post Hoc Analyses from reSURFACE 1. EADV Congress 2026 (Almirall De novo publication).
[xxii] [POSITIVE Study - Holistic View] A Holistic View of Treatment Success in Psoriasis: Long-Term Real-World Improvements in Psychological Well-Being and Health-Related Quality of Life With Tildrakizumab Patients with Psoriasis and Burdensome Symptoms (POSITIVE study). EADV Congress 2026 (Almirall De novo publication).
[xxiii] [POSITIVE Study - Psycholag] Psycholag in Moderate-to-Severe Psoriasis: Insights from the POSITIVE Study on Psychological Well-being and Treatment with Tildrakizumab. EADV Congress 2026 (Almirall De novo publication).
Press release
PDF 313.7KB
Published on 23 September 2026
Next week, we will be in Vienna for EADV 2026, one of the leading international congresses in dermatology, bringing together healthcare professionals, researchers, industry experts, and partners from around the world to share knowledge and explore the latest advances in skin health.
As a Gold Sponsor, we are proud to be part of this important scientific event and to contribute to the conversations shaping the future of Medical Dermatology. EADV provides a valuable platform for collaboration, learning, and the exchange of perspectives on some of the most pressing challenges and opportunities in dermatology today.
Throughout the congress, our teams will engage with the global dermatology community, participate in scientific discussions, and showcase our ongoing commitment to advancing Medical Dermatology through innovation, research, and partnership. The event also offers an opportunity to connect with peers and experts from across the field, fostering meaningful dialogue that ultimately supports better outcomes for people living with skin diseases.
During the week, we will be sharing highlights from the congress, key scientific insights, and moments from Vienna across our digital channels, offering a glimpse into the discussions and developments influencing the future of dermatological care.
EADV 2026 represents another opportunity to reinforce our commitment to supporting the dermatology community and advancing skin health to improve patients lives.
See you in Vienna!
#WeAreAlmirall #EADV2026
Published on 21 September 2026
As European Mobility Week highlights the importance of cleaner, more sustainable urban transport, we are proud to share how Almirall is advancing its climate ambitions through responsible mobility initiatives.
As part of our Act4Impact 2030 Sustainability Strategy, we are working to reduce the carbon footprint. One of the key ways we are doing this is through the gradual electrification of our fleet. By transitioning both sales and corporate vehicles to electric and hybrid alternatives, we are taking meaningful steps to lower emissions and support our broader climate goals.
However, sustainable mobility goes beyond the vehicles we use. It is also about the choices we make every day. Across our offices, we encourage employees to embrace lower-emission commuting options, including public transportation, walking, and cycling.
These initiatives reflect our belief that meaningful progress is achieved through collective action. Small changes, when adopted consistently across an organization, can contribute to significant long-term impact. By integrating sustainability into the way we move, we are helping build a culture that supports both environmental responsibility and employee wellbeing.
Our commitment to sustainable mobility is part of a broader ambition to create lasting value for people, society, and the planet through science-led action and measurable progress. Because when it comes to addressing climate change, every journey counts.
Discover more about our sustainability commitments and Act4Impact 2030 strategy: https://www.almirall.com/company/sustainability
Published on 17 September 2026
What does patient safety mean when living with a chronic skin condition?
On World Patient Safety Day, we join the World Health Organization in highlighting the importance of keeping patient safety at the center of every medical decision. For people living with conditions such as psoriasis, treatment is an ongoing journey that requires continuous care, monitoring, and support.
At Almirall, pharmacovigilance plays a key role in helping protect patients throughout their long-term journey. By continuously collecting and evaluating safety information from patients, healthcare professionals, clinical studies, and real-world use, we can identify potential safety signals and take timely action to help minimize risks.
To mark this day, colleagues from across Almirall shared what long-term safety means for them. Their perspectives highlight the importance of maintaining a patient-centered approach throughout the entire care journey.
This initiative reflects our commitment to advancing dermatological science while keeping patient well-being and safety at the core of everything we do. Because effective care is about more than managing a condition, it is about helping patients feel supported and protected every step of the way.
Published on 14 September 2026
What if the most challenging part of atopic dermatitis isn't always what we can see?
This World Atopic Eczema Day, we are proud to launch Atopics, an awareness film created with the support of AADA to bring greater understanding to the lived experience of people with atopic dermatitis. While the visible signs of the condition are often recognized, many of its day-to-day challenges remain unseen. Through authentic stories and a human perspective, the film shines a light on these experiences, particularly when the condition affects highly visible areas such as the face.
At Almirall, we believe that advancing understanding in medical dermatology requires more than scientific knowledge alone. It also means listening to patients, amplifying their voices, and fostering empathy alongside scientific rigor. By helping people see beyond the visible symptoms, we hope to contribute to a deeper awareness of the real impact atopic dermatitis can have on daily life.
In support of this commitment, we developed the Atopics campaign to encourage reflection, understanding, and conversation. Through personal stories, the film highlights the experiences behind the condition, reminding us that every patient journey is unique and deserving of recognition.
This initiative reflects our ongoing dedication to raising awareness of dermatological conditions and supporting a more informed and compassionate dialogue around skin health. Because behind every visible symptom, there is a person, a story, and an experience that deserves to be understood.
We invite you to watch Atopics and discover the people behind atopic dermatitis: https://www.almirall.com/patients/commitment/campaigns
Published on 2 September 2026
At Almirall, sustainability is an integral part of how we create long-term value and contribute positively to society. Guided by our Act4Impact strategy, we continuously work to embed responsible business practices into the way we operate, make decisions and drive innovation across our organisation.
This commitment has once again been recognised by EcoVadis. For the sixth consecutive year, we have been awarded the Platinum Medal, maintaining an outstanding score of 92/100 and placing us among the top 1% of more than 175,000 companies assessed worldwide.
More than a recognition, this achievement reflects the dedication of our teams, the strength of our governance and our collective effort to integrate sustainability into our everyday actions. It demonstrates how a shared commitment can help create meaningful impact for patients, society, our partners and the environment.
Being Uncommon By Nature means continuously challenging ourselves to do better and create lasting value. Through collaboration, accountability and a long-term perspective, we remain committed to advancing our sustainability ambitions and contributing to a more sustainable future for generations to come.
This milestone belongs to all the people across Almirall whose daily efforts make our progress possible, and it inspires us to continue turning commitment into action through Act4Impact.
Published on 10 August 2026
Almirall has entered a collaboration and licensing agreement with Chinese company CrystalO for the discovery and development of novel small molecules in medical dermatology.
The agreement builds on Almirall’s broader innovation strategy to identify innovative local R&D programmes that complement its in-house capabilities. It also reflects the company’s continued commitment to advancing differentiated treatments in areas of high unmet medical need in dermatology through strategic partnerships and scientific collaboration.
Under the terms of the agreement, CrystalO will be responsible for candidate discovery, optimisation, IND-enabling studies and early clinical development, with the aim of delivering clinical proof of concept (POC). Almirall will hold exclusive rights outside mainland China and will lead subsequent global development, manufacturing and commercialisation activities.
Commenting on the collaboration, Karl Ziegelbauer, Chief Scientific Officer at Almirall, said: “This collaboration with CrystalO marks another important step in advancing our innovation strategy in China and further reinforces our strong R&D pipeline in medical dermatology. We look forward to the potential this discovery partnership holds for delivering meaningful benefits to patients living with skin conditions worldwide.”
Dr. Zhang Jin, Founder and Chief Executive Officer of CrystalO, added: "We are honored to enter into a strategic collaboration with Almirall, a leading company with a strong global reputation in dermatology. This collaboration is a strong recognition of CrystalO's technology platform and R&D capabilities in ion channel drug discovery. We look forward to working closely with the Almirall team, fully leveraging the strengths of both parties, accelerating the development of innovative medicines, and bringing benefits to patients worldwide as early as possible".
Published on 10 August 2026
At Almirall, innovation begins with the curiosity, dedication and expertise of our teams. Every day, scientists, researchers and multidisciplinary experts work together to advance the understanding of skin diseases and address some of the most complex challenges in medical dermatology.
Driven by a deep commitment to science and a strong focus on patients’ needs, our teams combine research, collaboration and innovation to help transform insights into meaningful progress. This approach enables us to continue expanding knowledge of skin diseases and exploring new solutions that can make a difference in patients’ lives.
With a pipeline exclusively focused on medical dermatology, we are dedicated to advancing skin science and supporting continuous innovation in areas where significant unmet needs remain. Our work is guided not only by scientific excellence, but also by a determination to better understand the experiences of people living with skin conditions and the broader impact these diseases can have on their wellbeing.
Because behind every condition there is a person, our approach goes beyond the science itself. By bringing together scientific expertise, long-term ambition and a patient-centred mindset, we strive to contribute to better care and outcomes for those affected by skin diseases.
Through curiosity, collaboration and innovation, Almirall continues to advance medical dermatology with one clear purpose: helping improve patients’ lives and shaping a healthier future through science.
Published on 3 August 2026
At Almirall, our purpose is to help patients realize their hopes and dreams for a healthy life. This commitment guides everything we do, from advancing scientific knowledge in medical dermatology to fostering meaningful collaboration with healthcare professionals and patient communities around the world.
We recognize that skin diseases can have an impact far beyond physical symptoms, often affecting emotional, social and psychological well-being. Understanding this broader burden is essential to developing solutions that address the real needs of people living with skin conditions and help improve their quality of life.
Through our dedication to medical dermatology, we work to bring science closer to patients and healthcare professionals, transforming insights into innovation. By deepening our understanding of skin diseases and supporting scientific exchange, we aim to contribute to better care and outcomes for patients.
As a family-owned company, we take a long-term perspective, building trusted partnerships and investing in innovation that can create lasting value. Through the way
we collaborate, listen and learn, our teams bring this purpose to life every day, working alongside healthcare professionals, researchers and patient communities to advance care and support those affected by skin diseases.
By combining science, innovation and partnership, Almirall continues to pursue its purpose of transforming patients’ lives and contributing to a healthier future for generations to come.
Published on 24 July 2026
